SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran's potential blockbuster heart drug
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: trustmanic who wrote (24)2/5/1997 10:58:00 AM
From: Ron Kertesz   of 27
 
George,

Essentially, the meeting was a general introduction to Nortran for people who haven't heard about us yet as well as a review for some who had.

We at Nortran believe that we have a strong and unique technology foundation to develop drugs for many major medical conditions. We do need to let more people know about our company and this meeting was the start.

Also, as you point out, we have completed our Phase I trial with no serious adverse events or side-effects. We now are completeing our data analysis and reports for the regulatory agencies. The next step for RSD921 is licensing and clinical Phase II.

Ron
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News